enVVeno Medical Corporation (NASDAQ:NVNO - Get Free Report) Director Robert Gray acquired 3,500 shares of the stock in a transaction dated Tuesday, December 31st. The stock was bought at an average price of $2.94 per share, for a total transaction of $10,290.00. Following the purchase, the director now owns 11,155 shares of the company's stock, valued at $32,795.70. The trade was a 45.72 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.
enVVeno Medical Stock Performance
Shares of NVNO traded up $0.05 during trading hours on Thursday, reaching $3.07. 36,865 shares of the company traded hands, compared to its average volume of 115,468. The stock's fifty day moving average is $3.17 and its 200 day moving average is $4.26. enVVeno Medical Corporation has a 1-year low of $2.45 and a 1-year high of $6.97. The stock has a market cap of $53.85 million, a P/E ratio of -2.38 and a beta of 1.22.
enVVeno Medical (NASDAQ:NVNO - Get Free Report) last posted its quarterly earnings results on Thursday, October 31st. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.02). On average, equities research analysts predict that enVVeno Medical Corporation will post -1.3 EPS for the current year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Hohimer Wealth Management LLC acquired a new position in enVVeno Medical in the third quarter valued at about $286,000. Maven Securities LTD bought a new stake in shares of enVVeno Medical during the 3rd quarter valued at $295,000. Westside Investment Management Inc. lifted its stake in enVVeno Medical by 128.0% in the third quarter. Westside Investment Management Inc. now owns 88,375 shares of the company's stock valued at $297,000 after buying an additional 49,613 shares during the period. Corsair Capital Management L.P. bought a new position in enVVeno Medical during the 3rd quarter worth approximately $390,000. Finally, Geode Capital Management LLC grew its holdings in shares of enVVeno Medical by 7.8% in the 3rd quarter. Geode Capital Management LLC now owns 150,676 shares of the company's stock valued at $506,000 after buying an additional 10,902 shares during the period. Institutional investors own 34.71% of the company's stock.
About enVVeno Medical
(
Get Free Report)
enVVeno Medical Corporation Nasdaq: NVNO is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company's lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI).
Featured Stories
Before you consider enVVeno Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and enVVeno Medical wasn't on the list.
While enVVeno Medical currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
